✓ No fee unless you win✓ Free & confidential review✓ Board-certified trial attorney

Depo-Provera settlement talks put the focus on records, not rumors

Last reviewed: September 2, 2026

There is a lot of noise around the Depo-Provera meningioma cases right now. Some of it is useful. Some of it is way ahead of the public record.

Here is the careful version. Public litigation sources report that Pfizer and plaintiffs' leadership reached a settlement agreement in principle in MDL 3140 this summer. Public sources also report that the first bellwether schedule changed after that order. What we have not seen is just as important: no public settlement grid, no public payout numbers, and no final rule saying which claims are in or out.

For a woman who used Depo-Provera and later learned she had a meningioma, that means the next step is not guessing at a dollar figure. It is finding records.

Our main Depo-Provera lawsuit page covers the basic allegations in the MDL. This article is narrower. It is about the paperwork that may matter now that the case has moved from early litigation into settlement talks and continued causation proceedings for claims that may not resolve.

What changed this summer

The federal Depo-Provera cases are centralized in the Northern District of Florida before Judge M. Casey Rodgers. Plaintiffs generally allege that depot medroxyprogesterone acetate, the progestin in Depo-Provera and related products, is linked to intracranial meningioma and that U.S. warnings came too late.

The current public record points to three practical facts.

First, the docket grew quickly. A July 2026 JPML statistics report listed 5,830 pending actions in MDL 3140 and 5,916 total historical actions.

Second, a June 2026 court order reportedly confirmed a settlement agreement in principle for eligible federal MDL plaintiffs. That does not equal a finished settlement for everyone. It also does not mean Pfizer admitted wrongdoing.

Third, public summaries of the docket report that Rule 702, also called Daubert, remains relevant for claims outside the settlement framework. In plain English, the court still has to deal with what expert testimony can be used to prove general causation if a claim keeps moving toward contested litigation.

That is dry court language, but it has a very real effect. Cases are not reviewed in the abstract. They are reviewed through medical records, pharmacy records, clinic notes, dates, scans, and pathology.

The records problem is easy to underestimate

Depo-Provera is not like a pill bottle sitting in a bathroom cabinet. Many patients received the shot in an OB/GYN office, a health department clinic, a college clinic, a primary care office, or a family planning clinic. The medication may have been billed by the provider instead of filled at a retail pharmacy.

Years later, the record trail can be messy. A clinic closed. A chart moved to a hospital system. A last name changed. An old insurer has the billing history, but the patient never saw the claim detail at the time. None of that means there is no claim. It does mean someone has to rebuild the timeline with care.

The diagnosis side has its own trail. A meningioma may show up first on an emergency room scan, then get followed by MRI. Some patients have surgery. Some have radiation. Some are monitored because of tumor location or surgical risk. A short note saying "brain tumor" usually is not enough for a serious legal review.

What to collect before a review

Start with exposure. Look for records showing the dates of Depo-Provera, Depo-SubQ Provera 104, or DMPA injections. The best records usually come from the clinic that gave the shot, the prescribing doctor, pharmacy benefit records, insurance explanation-of-benefits records, or an old patient portal.

Then collect diagnosis records. That usually means the first MRI or CT report showing the meningioma, later imaging reports, neurology or neurosurgery notes, radiation oncology records if radiation was used, and operative or pathology reports if there was surgery.

If symptoms changed daily life, keep those records too. Follow-up visits, seizure medication, vision problems, hearing issues, work restrictions, rehabilitation, and repeat imaging can all help show what the diagnosis actually meant for the person living with it.

One caution: do not stop Depo-Provera, or any prescribed contraceptive, because of a lawsuit article. The FDA label itself tells clinicians what to do if a meningioma is diagnosed, but medical decisions belong with the patient and her doctor.

Why the FDA label still matters

Pfizer's current Depo-Provera prescribing information includes a meningioma warning. The label says meningiomas have been reported after long-term use of progestins, including medroxyprogesterone acetate, and says to discontinue Depo-Provera if a meningioma is diagnosed.

That warning does not prove any one person's case. It does give lawyers a date to look at when they review notice, warnings, and filing deadlines. Deadlines vary by state. In some cases, the date a patient first had reason to connect Depo-Provera with a meningioma may be part of the statute-of-limitations analysis.

The science in the background

The medical literature is why these cases exist. A 2024 BMJ national case-control study looked at women in France who had surgery for intracranial meningioma. For injectable medroxyprogesterone acetate, the study reported an odds ratio of 5.55, with the excess risk tied to prolonged use.

Other published work and litigation summaries discuss tumor patterns, multiple tumors, skull-base locations, and progesterone receptor expression. Those details are not trivia. They are the kinds of facts doctors and lawyers may compare against an individual claimant's imaging, pathology, and treatment history.

The hard part is that people do not live inside neat study tables. One person may have years of shots and a surgically removed tumor. Another may have shorter use, incomplete records, or a diagnosis that needs more medical clarification. A settlement process, if finalized, will almost certainly sort claims by facts like these.

If you have not filed yet

Do not assume the reported settlement framework means it is too late. Do not assume it means you are automatically included either. Public sources reviewed for this article did not disclose final eligibility rules.

A better first move is boring but useful: request the records. Ask the clinic for injection dates. Ask the imaging center for radiology reports and image discs or digital copies. Ask the hospital for operative and pathology reports. Ask old insurers for claim histories if the provider records are incomplete.

Mass Tort America also tracks other prescription-drug cases, including Suboxone dental injury claims and Ozempic and GLP-1 injury claims. A Depo-Provera review is different. It should stay centered on DMPA exposure, meningioma diagnosis, timing, and treatment.

Short FAQ

Has the Depo-Provera MDL fully settled?

Public sources report an agreement in principle for eligible federal MDL plaintiffs. They do not show a completed public settlement program with final payment amounts and final eligibility rules.

Does that reported agreement cover every claim?

No. Public reporting says the framework is for eligible MDL plaintiffs. Claims outside the criteria, newly reviewed claims, and state court cases may need separate analysis.

What records matter most?

Proof of injections and proof of diagnosis. In practice, that means injection records, pharmacy or billing records, MRI or CT reports, neurosurgery records, and pathology or operative reports if surgery occurred.

Should I change contraception now?

Talk with your prescribing clinician. Lawsuit information is not medical advice, and stopping a prescribed contraceptive without a medical plan can create its own risks.

Sources

Attorney Advertising. This article is for general information only. It is not medical advice or legal advice. Reading it or submitting a form does not create an attorney-client relationship. Every claim depends on the person's records, exposure history, deadlines, and applicable law.

Robert B. Baker, Board-Certified Civil Trial Attorney

Claims reviewed by Baker Legal Team
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →